A5001378539- Renal cell carcinoma treatment
- Renal and related cancers
- Economic and Financial Impacts of Cancer
- Cancer Genomics and Diagnostics
- Pharmacogenetics and Drug Metabolism
- Immune cells in cancer
- Pancreatic and Hepatic Oncology Research
- Drug Transport and Resistance Mechanisms
- Peptidase Inhibition and Analysis
- Chemokine receptors and signaling
- Cancer Immunotherapy and Biomarkers
- Computational Drug Discovery Methods
- Pharmaceutical studies and practices
- Tuberous Sclerosis Complex Research
- Drug Solubulity and Delivery Systems
- Receptor Mechanisms and Signaling
- Nanoplatforms for cancer theranostics
- Antibiotics Pharmacokinetics and Efficacy
Novartis (Switzerland)
2018-2021
Roche (Switzerland)
2012-2014
Abstract Purpose: PROTECT, a phase III, randomized, placebo-controlled study, evaluated pazopanib efficacy and safety in the adjuvant renal cell carcinoma setting. The relationship between exposure (Ctrough) was evaluated. Patients Methods: Evaluable steady-state blood trough concentrations were collected from 311 patients at week 3 or 5 (early Ctrough) 250 16 20 (late Ctrough). Pazopanib pharmacokinetic (PK) data analyzed via population model approach. Relationship Ctrough dose intensity...
3014 Background: Tumor-associated macrophages mediate intrinsic/acquired resistance to programmed death-1 (PD-1) inhibitors; these cells can be reduced by inhibiting the colony-stimulating factor-1 (CSF-1)/receptor pathway. Targeting CSF-1 with lacnotuzumab (MCS110), a high-affinity, humanized mAb, combined spartalizumab (PDR001), anti-PD-1 is hypothesized result in synergistic antitumor activity. Methods: This Phase Ib/II study (NCT02807844) assesses pts advanced melanoma, endometrial,...
Abstract Background: The CSF-1/CSF-1R (colony-stimulating factor-1) pathway plays a significant role in the tumor microenvironment via regulation of tumor-associated macrophages (TAMs). Lacnotuzumab (MCS110) is humanized monoclonal antibody against CSF-1. may counteract suppressive induced by CSF-1, potentially enhancing efficacy PD-1 inhibition. Methods: MCS110Z2102 phase 1b/2 study cancer patients with advanced malignancies treated lacnotuzumab combined inhibitor spartalizumab. Eligible...
<p>Mean (95% CI) of simulated pazopanib steady state exposure metrics on day 28 by dose in historical (black) and PROTECT (red) populations under fasted state</p>
<p>Prediction-corrected visual predictive checks of early (A) and late (B) Ctrough in study PROTECT</p>
<p>al population PK parameters for pazopanib</p>
<p>Baseline patient characteristics and variables used in population PK analysis</p>
<p>Quartiles for pazopanib steady-state early and late Ctrough</p>
<p>Clinical studies of pazopanib contributing to the historical dataset for population PK analyses</p>
<p>List of PROTECT Study investigators</p>
<p>List of PROTECT Study investigators</p>
<p>Baseline patient characteristics and variables used in population PK analysis</p>
<p>Mean (95% CI) of simulated pazopanib steady state exposure metrics on day 28 by dose in historical (black) and PROTECT (red) populations under fasted state</p>
<p>Prediction-corrected visual predictive checks of early (A) and late (B) Ctrough in study PROTECT</p>
<p>Quartiles for pazopanib steady-state early and late Ctrough</p>
<p>Clinical studies of pazopanib contributing to the historical dataset for population PK analyses</p>
<p>al population PK parameters for pazopanib</p>
<div>Abstract<p><b>Purpose:</b> PROTECT, a phase III, randomized, placebo-controlled study, evaluated pazopanib efficacy and safety in the adjuvant renal cell carcinoma setting. The relationship between exposure (C<sub>trough</sub>) was evaluated.</p><p><b>Patients Methods:</b> Evaluable steady-state blood trough concentrations were collected from 311 patients at week 3 or 5 (early C<sub>trough</sub>) 250 16 20 (late...
<div>Abstract<p><b>Purpose:</b> PROTECT, a phase III, randomized, placebo-controlled study, evaluated pazopanib efficacy and safety in the adjuvant renal cell carcinoma setting. The relationship between exposure (C<sub>trough</sub>) was evaluated.</p><p><b>Patients Methods:</b> Evaluable steady-state blood trough concentrations were collected from 311 patients at week 3 or 5 (early C<sub>trough</sub>) 250 16 20 (late...